Davis Mark E, Chen Zhuo Georgia, Shin Dong M
Chemical Engineering, California Institute of Technology, Pasadena, California 91125, USA.
Nat Rev Drug Discov. 2008 Sep;7(9):771-82. doi: 10.1038/nrd2614.
Nanoparticles--particles in the size range 1-100 nm--are emerging as a class of therapeutics for cancer. Early clinical results suggest that nanoparticle therapeutics can show enhanced efficacy, while simultaneously reducing side effects, owing to properties such as more targeted localization in tumours and active cellular uptake. Here, we highlight the features of nanoparticle therapeutics that distinguish them from previous anticancer therapies, and describe how these features provide the potential for therapeutic effects that are not achievable with other modalities. While large numbers of preclinical studies have been published, the emphasis here is placed on preclinical and clinical studies that are likely to affect clinical investigations and their implications for advancing the treatment of patients with cancer.
纳米颗粒——尺寸范围在1至100纳米之间的颗粒——正逐渐成为一类癌症治疗药物。早期临床结果表明,纳米颗粒治疗药物可显示出更高的疗效,同时由于其在肿瘤中更具靶向定位和活跃的细胞摄取等特性,还能减少副作用。在此,我们着重介绍纳米颗粒治疗药物有别于以往抗癌疗法的特征,并阐述这些特征如何为实现其他治疗方式无法达成的治疗效果提供潜力。虽然已经发表了大量临床前研究,但本文重点关注可能影响临床研究及其对推进癌症患者治疗意义的临床前和临床研究。